In August 2021, MOH announced changes to the financing of outpatient cancer treatment to help ensure the cost of cancer treatments and insurance premiums remain affordable over time. 

The changes to MediShield Life (MSHL) and Medisave (MSV) were implemented on 1 September 2022, while the change to Integrated Shield Plans (IPs) will take effect from 1 April 2023, upon policy purchase or renewal. More details can be found here. An overview of the cancer financing changes can be found in this brochure.  

The Cancer Drug List below shows the outpatient cancer treatments that are claimable and the corresponding MSHL and MSV limits. IP claim limits are set by the private insurers. The subsidy classes in the CDL apply to drugs at public healthcare institutions. Drugs can be subsidised under the Standard Drug List (SDL) or Medication Assistance Fund (MAF)

Frequently Asked Questions (FAQs)

Expand All | Collapse All

Why are there changes to cancer treatment financing?

Before 1 September 2022, MediShield Life pays up to $3,000/month for all cancer drugs and Integrated Shield Plans (IPs) often cover costs above that on an as-charged basis (i.e. no limit), with a small co-payment. 

Such a design meant that drug companies had no incentive charge lower prices for drug treatments that cost less. As a result, we ended up paying higher prices for many cancer drugs compared to other countries such as Australia, South Korea and United Kingdom. 

The changes to cancer treatment financing allow us to negotiate lower prices for cancer drugs, and ensure that cancer treatment costs and insurance premiums remain affordable for Singapore Residents in the long term. 

How will the revised chemotherapy benefits impact my claims from 1 September 2022?

Each cancer drug treatment on the Cancer Drug List (CDL) will have its own MediShield Life claim limits and MediSave withdrawal limits. 

The list of cancer drug treatments that are claimable under MediShield Life and MediSave, and their respective claim and withdrawal limits can be found below. Please also consult your doctor if you wish to find out whether the treatment that you are undergoing is on the list. 

The CDL will only come into effect for Integrated Shield Plans (IPs) on 1 April 2023. If you have an IP, you will continue to be covered under your current policy terms until it is renewed on or after 1 April 2023. 

For example, if your IP is up for renewal on 1 November 2023, the CDL and its revised limits will only apply then. Insurers may decide to cover treatments beyond the CDL under their riders, though the extent of coverage may vary. Your insurer should inform you of the details of your IP and rider coverage by end 2022.

Does the Cancer Drug List  also apply to inpatient cancer drug treatments?

No, inpatient cancer drug treatments are currently covered separately under the inpatient claim limits, together with other costs incurred during the inpatient stay. The MediShield Life inpatient daily ward and treatment charges claim limit is $1,000 per day for the first two days and $800 per day for the third and subsequent days of normal ward stay, and the MediSave inpatient daily hospital charges withdrawal limit is $550 for the first two days and $400 for the third and subsequent days of the ward stay.

If my treatment is not on the Cancer Drug List, will I still be covered?

MediShield Life and MediSave will only cover treatments on the Cancer Drug List (CDL) from 1 September 2022. 

For Integrated Shield Plans (IPs), the CDL will only come into effect from 1 April 2023 onwards, when an existing policy is renewed or a new policy is purchased. If you have an IP that is being renewed between 1 April 2023 and 30 September 2023, and are on a course of cancer drug treatment as of 31 March 2023, insurers have committed to preserve your current IP coverage until 30 September 2023.  

Riders will cover treatments beyond the CDL, though the extent of coverage may vary. Your insurer should inform you of the details of your IP and rider coverage by end 2022.

How are claim limits determined when more than one cancer drug is used in the treatment?

Patients who need more than one cancer drug treatment on the Cancer Drug List (CDL) in a month may claim up to the higher of the MediShield Life, MediSave and Integrated Shield Plan claim limits applicable for the individual treatments. 

For example, if a patient uses both Treatments X (MediShield Life claim limit of $2,000 & MediSave withdrawal limit of $600) and Y (MediShield Life claim limit of $1,000 & MediSave withdrawal limit of $600) in a month, the patient may claim no more than $2,000 from MediShield Life and $600 from MediSave in that month.

Please consult your doctors if you wish to clarify the claim limit that will apply for your treatment.

What is the criteria for inclusion in the Cancer Drug List?

Generally, the Cancer Drug List comprises of drugs that are clinically proven and more cost-effective in treating a particular cancer. A drug is clinically proven if it is registered with the Health Sciences Authority (HSA) for the particular clinical indication and has met the required standards of safety, quality and efficacy. A drug is cost effective if it provides good value in treating the particular cancer compared to existing standard of care, in terms of health benefits and cost.

Who assesses the cost-effectiveness of cancer drug treatments?

Companies are responsible for demonstrating the clinical- and cost-effectiveness of cancer drug treatments through the company-led submission process to the Agency for Care Effectiveness (ACE), Singapore’s national Health Technology Assessment (HTA) agency. 

Based on the evidence and companies’ price proposals, the MOH Drug Advisory Committee (DAC), chaired by the Director of Medical Services in MOH and comprising senior public sector doctors, pharmacists and MOH representatives makes recommendations to MOH for subsidy and MediShield Life coverage. 

More details on the processes and methods can be found on ACE’s website here.

How can I apply for treatments to be added to the CDL?

Since 2022, companies are responsible for providing evidence submissions and price proposals for their cancer drug treatments to be assessed for inclusion on the Cancer Drug List in parallel with their assessment for regulatory approval by HSA. More information can be found here

Clinicians can also request ACE to evaluate treatments for potential inclusion on the list using the attached application form. Clinicians who wish to leverage this route should prioritise treatments that are (i) considered standard of care for a rare cancer or (ii) for a specific subgroup of patients with no suitable registered treatment alternatives, and (iii) approved by at least one reference overseas regulatory authority.

All drug applications should be endorsed by the Chairman of the Medical Board (or equivalent body e.g. Medical Director) of the clinician’s institution before submission to MOH_DAC_Secretariat@moh.gov.sg, If you wish to check if a treatment is under evaluation prior to completing the form, please contact the MOH DAC Secretariat in the abovementioned email address. 

What happens if cancer drugs are subsequently removed from the CDL?

The CDL will be updated every 4 months. Generally, treatments will remain on the positive list unless there are strong reasons to remove them. Treatments may also have their claim limits adjusted (e.g. if a generic or biosimilar becomes available) or removed (e.g. if the company increases the price to non-cost-effective levels). 

Where there is a change in the CDL, the prevailing limits or listing based on the date of treatment will apply. If the patient had received the treatment before the drug was listed / after the drug was delisted, there would be no MSHL or IP payout. MOH will provide sufficient notice to medical institutions and insurers to implement any changes to the CDL, and patients are encouraged to switch to alternative subsidised treatments on the list, where possible.

Can a patient claim from the Cancer Drug Services limit if he is receiving a treatment that is not on the CDL?

Yes, patients may claim from the annual Cancer Drug Services limit even if the service was rendered for a cancer treatment not on the CDL (i.e. the claim limit is not specific to treatments on the CDL).

What if I need a treatment which is not on the Cancer Drug List (CDL) or is on the CDL but unsubsidised, and I cannot afford the treatment without insurance?

We encourage you to discuss with your doctor if there are suitable alternative treatments on the CDL that are subsidised and covered by insurance. However, if switching treatments is not feasible, there is support to help you if you do face difficulty affording your treatment.

If you are a subsidised patient, you can approach a Medical Social Worker (MSW) in your Public Health Institution (PHI) for financial assistance such as MediFund. If you are a private patient, you can approach your doctor to refer you to a PHI for subsidised care. The PHI’s medical team will review your treatment plan and provide financial counselling (e.g., eligibility for subsidies) before you decide whether to transfer.

To help existing patients during this transition, MOH will provide additional financial support for all PHI patients without an IP, and who had started treatments that are unsubsidised or not on the CDL before 1 September 2022. Insurers, on their part, will continue their current coverage until 30 September 2023 for patients with IP that are being renewed between 1 April 2023 and 30 September 2023, and who are on a course of cancer drug treatment as of 31 March 2023.

Cancer Drug List

The subsidy class, and MediShield Life and MediSave limits may change from time to time. The prevailing subsidy class, and MediShield Life and MediSave limits will be applied at the point the patient receives treatment. Brands specified in the 'subsidy class' column refers to the eligibility for SDL subsidy only. Other brand(s) of the same active ingredient, while not eligible for SDL subsidy, will follow the same MediShield Life (MSHL), MediSave and IP coverage.

If more than one cancer drug from the list is used in a month, the patient may claim up to the amounts not exceeding the highest MediShield Life and MediSave claim limits applicable for the individual drugs. For example, if a patient uses both Drugs A (MediShield Life claim limit of $2,000 & MediSave withdrawal limit of $600) and B (MediShield Life claim limit of $1,000 & MediSave withdrawal limit of $600) in a month, the patient may claim no more than $2,000 from MediShield Life and $600 from MediSave in that month.

Expand All | Collapse All

Explanatory Note on Category

Refers to the MediShield Life claim limit tiers, as prescribed in the Sixth Schedule of the MediShield Life Scheme Regulations 2015. In relation to the First Schedule of the Central Provident Fund (Medisave Account Withdrawals) Regulations, categories 1 to 27 are considered the “first tier” of the CDL, while categories 28 to 48 are considered the “second tier” of the CDL.

Category MediShield Life Claim Limit per month ($)
1 $200.00
2 $400.00
3 $600.00
4 $800.00
5 $1,000.00
6 $1,200.00
7 $1,400.00
8 $1,600.00
9 $1,800.00
10 $2,000.00
12 $2,400.00
15 $3,000.00
16 $3,200.00
19 $3,800.00
26 $5,200.00
27 $5,400.00
46 $9,200.00
48 $9,600.00
Updated 1 Sep 2022
Cancer type ↕ Active ingredient ↕ Dosage Form(s) and Strength(s) ↕ Brand(s) ↕ Clinical indication ↕ Subsidy Class ↕ MediShield Life Claim Limit per month ↕ MediSave Withdrawal Limit per month ↕ Category ↕
Skin cancer 5-fluorouracil 5-fluorouracil cream (5%) - Treatment of actinic keratosis, Bowen’s disease, or superficial basal cell carcinoma. No subsidy $ 200 $ 600 1
Breast cancer Abemaciclib Abemaciclib tablet (50 mg, 100 mg, 150 mg) Verzenio Abemaciclib in combination with an aromatase inhibitor as initial endocrine-based therapy for HR positive, HER2 negative, advanced or metastatic breast cancer. MAF $ 800 $ 600 4
Breast cancer Abemaciclib Abemaciclib tablet (50 mg, 100 mg, 150 mg) Verzenio Abemaciclib in combination with fulvestrant for treating HR positive, HER2 negative, advanced or metastatic breast cancer in patients who have received prior endocrine therapy. MAF $ 800 $ 600 4
Others Abiraterone Abiraterone tablet (250 mg, 500 mg, 1000 mg) - For cancer treatment. SDL
(Abiranat)
$ 400 $ 600 2
Leukaemia Acalabrutinib Acalabrutinib capsule (100 mg) Calquence Monotherapy for chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who have received at least one prior therapy. MAF $ 2,000 $ 600 10
Leukaemia Acalabrutinib Acalabrutinib capsule (100 mg) Calquence Monotherapy for previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who are unsuitable for fludarabine-based therapy. MAF $ 2,000 $ 600 10
Lymphoma Acalabrutinib Acalabrutinib capsule (100 mg) Calquence Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. MAF $ 2,000 $ 600 10
Leukaemia Acalabrutinib Acalabrutinib capsule (100 mg) Calquence Acalabrutinib in combination with obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in patients who are unsuitable for fludarabine-based therapy. No subsidy $ 2,000 $ 600 10
Lung cancer Afatinib Afatinib tablet (20 mg, 30 mg, 40 mg) Giotrif Treatment of locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer. MAF $ 600 $ 600 3
Colorectal cancer Aflibercept Aflibercept concentrate for solution for infusion (100 mg/4 mL) Zaltrap Aflibercept in combination with FOLFIRI for treating metastatic colorectal cancer that has progressed on first-line systemic therapy. No subsidy $ 600 $ 600 3
Lung cancer Alectinib Alectinib capsule (150 mg) Alecensa Treatment of locally advanced or metastatic ALK mutation-positive non-small-cell lung cancer. MAF $ 2,000 $ 600 10
Breast cancer Alpelisib Alpelisib tablet (150 mg, 200 mg, 200mg + 50 mg pack) Piqray Alpelisib in combination with fulvestrant for treating HR-positive, HER2-negative, advanced breast cancer in patients with a PIK3CA mutation after disease progression following an endocrine-based regimen. No subsidy $ 800 $ 600 4
Myeloproliferative neoplasms Anagrelide Anagrelide capsule (0.5 mg) Agrylin Reduction of elevated platelet counts in patients with essential thrombocythaemia who are intolerant to their existing therapy or for whom other therapies are not considered appropriate. MAF $ 200 $ 600 1
Breast cancer Anastrozole Anastrozole tablet (1 mg) - Treatment of hormone receptor positive, postmenopausal women with early and advanced breast cancer. MAF $ 200 $ 600 1
Prostate cancer Apalutamide Apalutamide tablet (60 mg) Erleada Treatment of patients with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). No subsidy $ 400 $ 600 2
Prostate cancer Apalutamide Apalutamide tablet (60 mg) Erleada Treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). No subsidy $ 400 $ 600 2
Others Arsenic trioxide Arsenic trioxide injection (10 mg) - For cancer treatment. No subsidy $ 3,000 $ 600 15
Liver cancer Atezolizumab Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL) Tecentriq Atezolizumab in combination with bevacizumab biosimilar (subsidised brand) for treating advanced unresectable hepatocellular carcinoma in patients who have not received prior systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system. MAF $ 1,800 $ 600 9
Lung cancer Atezolizumab Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL) Tecentriq Atezolizumab in combination with a platinum agent and etoposide, for untreated extensive-stage small-cell lung cancer. MAF $ 1,800 $ 600 9
Lung cancer Atezolizumab Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL) Tecentriq Atezolizumab in combination with bevacizumab biosimilar (subsidised brand), paclitaxel and carboplatin, for the treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who had not received prior chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses. MAF $ 1,800 $ 600 9
Lung cancer Atezolizumab Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL) Tecentriq For untreated metastatic non-small cell lung cancer (NSCLC), in patients whose tumours express PD-L1 with a tumour proportion score ≥50%, with no EGFR or ALK genomic tumour aberrations. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses. MAF $ 1,800 $ 600 9
Lung cancer Atezolizumab Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL) Tecentriq Treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses. MAF $ 1,800 $ 600 9
Bladder cancer Atezolizumab Atezolizumab concentrate for solution for infusion (840 mg/14 ml, 1200 mg/20 ml) Tecentriq Treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) after receiving platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for locally advanced or metastatic UC. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses. No subsidy $ 1,800 $ 600 9
Bladder cancer Atezolizumab Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL) Tecentriq Treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses. No subsidy $ 1,800 $ 600 9
Bladder cancer Atezolizumab Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL) Tecentriq Treatment of patients with locally advanced or metastatic urothelial carcinoma whose tumours express PD-L1 (PD-L1 stained tumour-infiltrating immune cells covering ≥5% of the tumour area), and who are not eligible for cisplatin-containing chemotherapy. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses. No subsidy $ 1,800 $ 600 9
Breast cancer Atezolizumab Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL) Tecentriq Atezolizumab in combination with nab-paclitaxel for treating patients with unresectable, locally advanced, or metastatic triple negative breast cancer whose tumours have PD-L1 expression ≥1% and who have not received prior chemotherapy for metastatic disease. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses. No subsidy $ 1,800 $ 600 9
Liver cancer Atezolizumab Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL) Tecentriq Atezolizumab in combination with bevacizumab (non-subsidised brand) for treating advanced unresectable hepatocellular carcinoma in patients who have not received prior systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system. No subsidy $ 1,800 $ 600 9
Lung cancer Atezolizumab Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL) Tecentriq Atezolizumab in combination with bevacizumab (non-subsidised brand), paclitaxel and carboplatin, for the treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who had not received prior chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses. No subsidy $ 1,800 $ 600 9
Lung cancer Atezolizumab Atezolizumab concentrate for solution for infusion (840 mg/14 mL, 1200 mg/20 mL) Tecentriq Atezolizumab in combination with nab-paclitaxel and carboplatin, for untreated metastatic non-squamous non-small cell lung cancer (NSCLC), in patients with no EGFR or ALK genomic tumour aberrations. Treatment with atezolizumab should be stopped at 2 years, or earlier if disease progresses. No subsidy $ 1,800 $ 600 9
Bladder cancer Avelumab Avelumab concentrate for solution for infusion (200 mg/10 mL) Bavencio Maintenance treatment of locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-based chemotherapy. Avelumab may be given at a dose of 10 mg/kg up to a maximum of 800 mg, every 2 weeks. MAF $ 1,800 $ 600 9
Merkel cell cancer Avelumab Avelumab concentrate for solution for infusion (200 mg/10 mL) Bavencio Treatment of metastatic merkel cell carcinoma. Avelumab may be given at a dose of 10 mg/kg up to a maximum of 800 mg, every 2 weeks. Treatment with avelumab should be stopped at 2 years, or earlier if disease progresses. MAF $ 1,800 $ 600 9
Renal cancer Avelumab plus axitinib Avelumab concentrate for solution for infusion (200 mg/10 mL)

Axitinib tablet (1 mg, 5 mg)
Bavencio


Inlyta
Avelumab in combination with axitinib for untreated advanced renal cell carcinoma. Avelumab may be given at a dose of 10 mg/kg up to a maximum of 800 mg, every 2 weeks. Treatment with avelumab should be stopped at 2 years, or earlier if disease progresses. MAF $ 3,000 $ 600 15
Renal cancer Axitinib Axitinib tablet (1 mg, 5 mg) Inlyta For previously treated advanced renal cell carcinoma. MAF $ 1,000 $ 600 5
Others Azacitidine Azacitidine injection (100 mg) - For cancer treatment. SDL $ 600 $ 600 3
Others Bacillus Calmette-Guerin (BCG) Bacillus Calmette-Guerin (BCG) solution for intravesical use (12.5 mg, 40 mg, 80 mg) - For cancer treatment. SDL $ 600 $ 600 3
Others Bendamustine Bendamustine concentrate for infusion (25 mg and 100 mg) - For cancer treatment. SDL $ 1,000 $ 600 5
Others Bevacizumab Bevacizumab concentrate for solution for infusion (100 mg/4 mL, 400 mg/16 mL) Avastin For cancer treatment. No subsidy $ 600 $ 600 3
Others Bevacizumab Bevacizumab biosimilar concentrate for solution for infusion (100 mg/4 mL, 400 mg/16 mL) Mvasi For cancer treatment. SDL (Mvasi) $ 600 $ 600 3
Lymphoma Bexarotene Bexarotene capsule (75 mg) - Treatment of cutaneous T-cell lymphoma in adults who have received at least one prior systemic therapy. No subsidy $ 1,800 $ 600 9
Others Bicalutamide Bicalutamide tablet (50 mg) - For cancer treatment. SDL $ 200 $ 600 1
Others Bleomycin Bleomycin injection (15 USP unit) - For cancer treatment. SDL $ 400 $ 600 2
Leukaemia Blinatumomab Blinatumomab powder for infusion (35 mcg vial) Blincyto Treatment of B-precursor acute lymphoblastic leukaemia in first or subsequent complete remission with minimal residual disease (MRD) greater than or equal to 0.1% for:
- up to a maximum of one cycle for induction in a lifetime;
- and up to three additional cycles for consolidation in a lifetime in patients who are MRD negative.

Complete remission is defined as a patient who:
a) has 5% or less bone marrow blasts; and
b) has no evidence of disease; and
c) has a full recovery of peripheral blood counts with platelet count of more than 100,000 per microlitre; and
d) absolute neutrophil count of more than 1,000 per microlitre
MAF $ 9,600 $ 1,200 48
Leukaemia Blinatumomab Blinatumomab powder for infusion (35 mcg vial) Blincyto Treatment of relapsed or refractory B-precursor acute lymphoblastic leukaemia (r/r B-ALL) for:
- up to a maximum of two cycles for induction in a lifetime; and
- up to three additional cycles for consolidation in a lifetime in patients who achieve a complete response after induction.

Patients with Philadelphia chromosome positive disease must have previously received a tyrosine kinase inhibitor before receiving blinatumomab.
Patients must not have received blinatumomab previously for the treatment of minimal residual disease (MRD)-positive B-ALL OR patients must have had a relapse-free period of at least six months following completion of treatment with blinatumomab for MRD.

Complete response is defined as a patient who:
- has 5% or less bone marrow blasts; and
- has no evidence of disease; and
- has platelet count of more than 50,000 per microlitre; and
- has absolute neutrophil count of more than 500 per microlitre.



MAF $ 9,600 $ 1,200 48
Others Bortezomib Bortezomib injection (3.5mg) - For cancer treatment. SDL
(Pfizer Bortezomib)
$ 1,400 $ 600 7
Lymphoma Brentuximab vedotin Brentuximab vedotin powder for concentrate for solution for infusion (50 mg) Adcetris Brentuximab in combination with cyclophosphamide, doxorubicin and prednisone (CHP), for previously untreated CD30+ peripheral T-cell lymphoma. MAF $ 1,800 $ 600 9
Lymphoma Brentuximab vedotin Brentuximab vedotin powder for concentrate for solution for infusion (50 mg) Adcetris Treatment of patients with CD30+ cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy. Treatment should be stopped at 16 cycles, or earlier if disease progresses. MAF $ 1,800 $ 600 9
Lymphoma Brentuximab vedotin Brentuximab vedotin powder for concentrate for solution for infusion (50 mg) Adcetris Treatment of patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL):
1. following autologous stem cell transplant (ASCT) or
2. following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option. Treatment should be stopped at 16 cycles, or earlier if disease progresses.
MAF $ 1,800 $ 600 9
Lymphoma Brentuximab vedotin Brentuximab vedotin powder for concentrate for solution for infusion (50 mg) Adcetris Treatment of relapsed or refractory systemic anaplastic large cell lymphoma. Treatment should be stopped at 16 cycles, or earlier if disease progresses. MAF $ 1,800 $ 600 9
Lymphoma Brentuximab vedotin Brentuximab vedotin powder for concentrate for solution for infusion (50 mg) Adcetris Consolidation treatment of patients with CD30+ Hodgkin lymphoma (HL) who are at increased risk of relapse or progression following an autologous stem cell transplant (ASCT). Treatment should be stopped at 16 cycles, or earlier if disease progresses. MAF $ 1,800 $ 600 9
Lymphoma Brentuximab vedotin Brentuximab vedotin powder for concentrate for solution for infusion (50 mg) Adcetris Brentuximab vedotin in combination with doxorubicin, vinblastine and dacarbazine (AVD), for treating patients with previously untreated CD30+ advanced classic Hodgkin lymphoma (cHL) who are intolerant or have contraindications to bleomycin. MAF $ 1,800 $ 600 9
Lymphoma Brentuximab vedotin Brentuximab vedotin powder for concentrate for solution for infusion (50 mg) Adcetris Brentuximab vedotin in combination with doxorubicin, vinblastine and dacarbazine (AVD), for treating patients with previously untreated CD30+ advanced classic Hodgkin lymphoma (cHL). No subsidy $ 1,800 $ 600 9
Lung cancer Brigatinib Brigatinib tablet (30 mg, 90 mg, 180 mg) Alunbrig Treatment of locally advanced or metastatic ALK mutation-positive non-small-cell lung cancer. MAF $ 2,000 $ 600 10
Others Bromocriptine Bromocriptine tablet (2.5 mg) - For cancer treatment. SDL $ 200 $ 600 1
Others Busulfan Busulfan tablet (2 mg) - For cancer treatment. SDL $ 200 $ 600 1
Prostate cancer Cabazitaxel Cabazitaxel injection (60 mg/1.5 mL) Jevtana Cabazitaxel in combination with prednisolone: for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing regimen. No subsidy $ 1,400 $ 600 7
Neuroendocrine Cabergoline Cabergoline tablet (0.5 mg) Dostinex As a 2nd line agent for the management of hyperprolactinaemia in patients who have failed to respond or who are unable to tolerate bromocriptine. MAF $ 200 $ 600 1
Liver cancer Cabozantinib Cabozantinib tablet (20 mg, 40 mg, 60 mg) Cabometyx Treatment of advanced unresectable hepatocellular carcinoma in patients with disease progression after 1 or more prior lines of systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system. MAF $ 1,800 $ 600 9
Renal cancer Cabozantinib Cabozantinib tablet (20 mg, 40 mg, 60 mg) Cabometyx For previously treated advanced renal cell carcinoma. MAF $ 1,800 $ 600 9
Renal cancer Cabozantinib Cabozantinib tablet (20 mg, 40 mg, 60 mg) Cabometyx For untreated intermediate- or poor-risk advanced renal cell carcinoma. MAF $ 1,800 $ 600 9
Others Capecitabine Capecitabine tablet (150 mg, 500 mg) - For cancer treatment. SDL $ 200 $ 600 1
Others Carboplatin Carboplatin vial (150 mg/15 mL, 450 mg/45 mL) - For cancer treatment. SDL $ 200 $ 600 1
Multiple myeloma Carfilzomib Carfilzomib powder for solution for infusion (30 mg) Kyprolis Carfilzomib in combination with dexamethasone for patients with multiple myeloma who have received at least one prior therapy. MAF $ 2,000 $ 600 10
Multiple myeloma Carfilzomib Carfilzomib powder for solution for infusion (30 mg) Kyprolis Carfilzomib in combination with lenalidomide or thalidomide or cyclophosphamide, plus dexamethasone, for patients with multiple myeloma who have received at least one prior therapy. Treatment with carfilzomib should be stopped after 18 cycles, or earlier if disease progresses. MAF $ 2,000 $ 600 10
Others Carmustine Carmustine injection (100 mg) BiCNU For cancer treatment. SDL $ 2,000 $ 600 10
Others Ceritinib Ceritinib capsule (150 mg) Zykadia For cancer treatment. SDL $ 1,000 $ 600 5
Others Cetuximab Cetuximab solution for infusion (100 mg/20 mL) Erbitux For cancer treatment. SDL $ 1,000 $ 600 5
Others Chlorambucil Chlorambucil tablet (2 mg) Leukeran For cancer treatment. SDL $ 400 $ 600 2
Others Cisplatin Cisplatin injection (50 mg/50 mL, 100 mg/100 mL injection) - For cancer treatment. SDL $ 200 $ 600 1
Leukaemia Cladribine Cladribine injection (10 mg/5 mL, 10 mg/10 mL) - Treatment of hairy cell leukaemia. No subsidy $ 3,000 $ 600 15
Lymphoma Copanlisib Copanlisib injection (60 mg) Aliqopa Treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies. No subsidy $ 1,800 $ 600 9
Lymphoma Crisantaspase Crisantaspase injection (10,000 IU) Erwinase For cancer treatment in patients who have developed hypersensitivity to E.coli-derived asparaginase. No subsidy $ 1,000 $ 600 5
Lung cancer Crizotinib Crizotinib capsule (200 mg, 250 mg) Xalkori Treatment of patients with locally advanced or metastatic ROS1 mutation-positive non-small-cell lung cancer. Patients must not have received prior treatment with other ROS1 inhibitors. No subsidy $ 3,000 $ 600 15
Lymphoma Crizotinib Crizotinib capsule (200 mg, 250 mg) Xalkori Paediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma that is ALK-positive. No subsidy $ 3,000 $ 600 15
Others Cyclophosphamide Cyclophosphamide vial (1 g) and tablet (50 mg) Endoxan For cancer treatment. SDL $ 200 $ 600 1
Others Cyproterone Cyproterone tablet (50 mg) - For cancer treatment. SDL $ 200 $ 600 1
Others Cytarabine Cytarabine vial (1 g/10 mL) - For cancer treatment. SDL $ 400 $ 600 2
Lung cancer Dabrafenib plus trametinib Dabrafenib capsule (50 mg, 75 mg)
Trametinib tablet (0.5 mg, 2 mg)
Tafinlar

Mekinist
Dabrafenib in combination with trametinib for the treatment of advanced non-small-cell lung cancer (NSCLC) in patients with a BRAF V600 mutation. MAF $ 3,800 $ 600 19
Skin cancer Dabrafenib plus trametinib Dabrafenib capsule (50 mg, 75 mg)
Trametinib tablet (0.5 mg, 2 mg)
Tafinlar

Mekinist
Dabrafenib in combination with trametinib for the treatment of advanced unresectable or metastatic malignant melanoma in patients with a BRAF V600 mutation. Patients must not have received prior treatment with a BRAF/MEK inhibitor for unresectable or metastatic melanoma. MAF $ 3,800 $ 600 19
Thyroid cancer Dabrafenib plus trametinib Dabrafenib capsule (50 mg, 75 mg)
Trametinib tablet (0.5 mg, 2 mg)
Tafinlar

Mekinist
Dabrafenib in combination with trametinib for treating locally advanced or metastatic anaplastic thyroid cancer in patients with a BRAF V600 mutation and with no satisfactory locoregional treatment options. MAF $ 3,800 $ 600 19
Skin cancer Dabrafenib plus trametinib Dabrafenib capsule (50 mg, 75 mg)
Trametinib tablet (0.5 mg, 2 mg)
Tafinlar

Mekinist
Dabrafenib in combination with trametinib for the adjuvant treatment of completely resected malignant melanoma in patients with BRAF V600 mutation-positive disease and lymph node involvement. Maximum duration of treatment: 12 months. No subsidy $ 3,800 $ 600 19
Others Dacarbazine Dacarbazine vial (200 mg) - For cancer treatment. SDL $ 600 $ 600 3
Others Dacomitinib Dacomitinib tablet (15 mg, 30 mg, 45 mg) Vizimpro For cancer treatment. SDL $ 600 $ 600 3
Others Dactinomycin Dactinomycin vial (500 mcg) - For cancer treatment. SDL $ 1,600 $ 600 8
Multiple myeloma Daratumumab Daratumumab concentrate for solution for infusion (100 mg/5 mL, 400 mg/20 mL) and SC solution for injection (1800 mg/15 mL) Darzalex Daratumumab in combination with bortezomib and dexamethasone for patients with multiple myeloma who have received at least one prior therapy. No subsidy $ 2,000 $ 600 10
Multiple myeloma Daratumumab Daratumumab concentrate for solution for infusion (100 mg/5 mL, 400 mg/20 mL) and SC solution for injection (1800 mg/15 mL) Darzalex Daratumumab in combination with bortezomib, thalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are eligible for an autologous stem cell transplant. No subsidy $ 2,000 $ 600 10
Multiple myeloma Daratumumab Daratumumab concentrate for solution for infusion (100 mg/5 mL, 400 mg/20 mL) and SC solution for injection (1800 mg/15 mL) Darzalex Daratumumab in combination with lenalidomide and dexamethasone for patients with multiple myeloma who have received at least one prior therapy. No subsidy $ 2,000 $ 600 10
Multiple myeloma Daratumumab Daratumumab concentrate for solution for infusion (100 mg/5 mL, 400 mg/20 mL) and SC solution for injection (1800 mg/15 mL) Darzalex Daratumumab in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are ineligible for an autologous stem cell transplant. No subsidy $ 2,000 $ 600 10
Prostate cancer Darolutamide Darolutamide tablet (300 mg) Nubeqa Treatment of patients with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). No subsidy $ 400 $ 600 2
Leukaemia Dasatinib Dasatinib tablet (20 mg, 50 mg, 70 mg) Sprycel Treatment of adults with treatment-resistant or treatment-intolerant chronic myeloid leukemia (CML) in chronic phase, accelerated phase, or myeloid or lymphoid blast phase or children with treatment-resistant or treatment-intolerant CML in chronic phase. MAF $ 1,200 $ 600 6
Leukaemia Dasatinib Dasatinib tablet (20 mg, 50 mg, 70 mg) Sprycel Treatment of newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia in combination with chemotherapy. MAF $ 1,200 $ 600 6
Leukaemia Dasatinib Dasatinib tablet (20 mg, 50 mg, 70 mg) Sprycel Treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase. MAF $ 1,200 $ 600 6
Leukaemia Dasatinib Dasatinib tablet (20 mg, 50 mg, 70 mg) Sprycel Treatment of patients with Philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior treatment with imatinib. MAF $ 1,200 $ 600 6
Others Daunorubicin Daunorubicin vial (20 mg ) - For cancer treatment. SDL $ 400 $ 600 2
Others Decitabine Decitabine 50mg injection For cancer treatment. No subsidy $ 600 $ 600 3
Prostate cancer Degarelix Degarelix injection (80 mg, 120 mg) Firmagon Treatment of patients with advanced hormone-dependent prostate cancer. MAF $ 200 $ 600 1
Others Desmopressin Desmopressin nasal spray (10 mcg/dose) Minirin
Presinex
For cancer treatment. SDL $ 200 $ 600 1
Others Desmopressin Desmopressin tablet (0.1 mg, 0.2 mg) Minirin For cancer treatment. SDL $ 400 $ 600 2
Others Dexamethasone Dexamethasone injection (4 mg) and tablet (0.5mg, 4 mg) - For cancer treatment. SDL $ 200 $ 600 1
Others Docetaxel Docetaxel vial (20 mg , 80 mg, 160 mg) - For cancer treatment. SDL $ 200 $ 600 1
Others Doxorubicin Doxorubicin vial (50 mg) - For cancer treatment. SDL $ 200 $ 600 1
Lung cancer Durvalumab Durvalumab concentrate for solution for infusion (120 mg/2.4 mL, 500 mg/10 mL) Imfinzi Consolidation treatment of patients with locally advanced, unresectable NSCLC whose disease has not progressed following platinum-based chemo-radiation therapy.
Treatment should be continued until disease progression or unacceptable toxicity or for a maximum of 12 months.
MAF $ 1,800 $ 600 9
Lung cancer Durvalumab Durvalumab concentrate for solution for infusion (120 mg/2.4 mL, 500 mg/10 mL) Imfinzi Durvalumab in combination with a platinum agent and etoposide, for untreated extensive-stage small-cell lung cancer. MAF $ 1,800 $ 600 9
Lung cancer Entrectinib Entrectinib capsule (100 mg, 200 mg) Rozlytrek Treatment of patients with locally advanced or metastatic ROS1 mutation-positive non-small-cell lung cancer. Patients must not have received prior treatment with other ROS1 inhibitors. No subsidy $ 3,000 $ 600 15
Tumour agnostic Entrectinib Entrectinib capsule (100 mg, 200 mg) Rozlytrek Treatment of patients with solid tumours that:
- have a NTRK gene fusion without a known acquired resistance mutation,
- are metastatic or where surgical resection is likely to result in severe morbidity, and
- have no satisfactory alternative treatments or that have progressed following treatment.
No subsidy $ 3,000 $ 600 15
Prostate cancer Enzalutamide Enzalutamide capsule (40 mg) Xtandi Treatment of patients with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC). MAF $ 400 $ 600 2
Prostate cancer Enzalutamide Enzalutamide capsule (40 mg) Xtandi Treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). MAF $ 400 $ 600 2
Prostate cancer Enzalutamide Enzalutamide capsule (40 mg) Xtandi Treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). MAF $ 400 $ 600 2
Others Epirubicin Epirubicin injection (50 mg/25 mL) - For cancer treatment. SDL $ 800 $ 600 4
Bladder cancer Erdafitinib Erdafitinib tablet (3 mg, 4 mg, 5 mg) Balversa Treatment of patients with locally advanced or metastatic urothelial carcinoma, whose tumours have susceptible FGFR3 genetic alterations, and who have disease progression during or following at least one line of prior chemotherapy including within 12 months of neoadjuvant or adjuvant chemotherapy. No subsidy $ 1,800 $ 600 9
Breast cancer Eribulin mesylate Eribulin mesylate solution for injection (1 mg/2 mL) Halaven Treatment of locally advanced or metastatic breast cancer in patients whose disease has progressed after at least two chemotherapy regimens for advanced disease. MAF $ 1,200 $ 600 6
Sarcoma Eribulin mesylate Eribulin mesylate solution for injection (1 mg/2 mL) Halaven Treatment of patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease. MAF $ 1,200 $ 600 6
Others Erlotinib Erlotinib tablet (100 mg, 150 mg) - For cancer treatment. SDL
(Inerlotinib)
$ 200 $ 600 1
Others Etoposide Etoposide capsule (50 mg) - For cancer treatment. SDL $ 600 $ 600 3
Others Etoposide Etoposide vial (100 mg/5 mL) - For cancer treatment. SDL $ 200 $ 600 1
Neuroendocrine Everolimus Everolimus tablet (2.5 mg, 5 mg, 10 mg) Afinitor Treatment of unresectable or metastatic, well-differentiated, non-functional neuroendocrine tumours of gastrointestinal or lung origin and with progressive disease. MAF $ 1,200 $ 600 6
Neuroendocrine Everolimus Everolimus tablet (2.5 mg, 5 mg, 10 mg) Afinitor Treatment of unresectable, locally advanced or metastatic neuroendocrine tumours of pancreatic origin and with progressive disease. MAF $ 1,200 $ 600 6
Breast cancer Everolimus Everolimus tablet (2.5 mg, 5 mg, 10 mg) Afinitor Everolimus in combination with exemestane for HR positive, HER2/neu negative advanced breast cancer, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor. No subsidy $ 1,200 $ 600 6
Renal cancer Everolimus Everolimus tablet (2.5 mg, 5 mg, 10 mg) Afinitor For previously treated advanced renal cell carcinoma. No subsidy $ 1,200 $ 600 6
Others Exemestane Exemestane tablet (25 mg) - For cancer treatment. SDL $ 200 $ 600 1
Others Fludarabine Fludarabine injection (50 mg) - For cancer treatment. SDL $ 600 $ 600 3
Others Fluorouracil Fluorouracil vial (500 mg/10 mL, 1g/20 mL, 5g/100 mL) - For cancer treatment. SDL $ 200 $ 600 1
Prostate cancer Flutamide Flutamide tablet (250 mg) - Flutamide in combination with luteinising hormone-releasing hormone (LHRH) agonists for previously untreated advanced prostatic carcinoma. No subsidy $ 200 $ 600 1
Others Folinic acid Folinic acid vial (50 mg/5 mL, 300 mg/30 mL) - For cancer treatment. SDL $ 200 $ 600 1
Others Fulvestrant Fulvestrant solution for injection in pre-filled syringe (250 mg/5 mL) - For cancer treatment. SDL
(Femcord)
$ 200 $ 600 1
Others Gefitinib Gefitinib tablet (250 mg) - For cancer treatment. SDL
(Ingefitinib)
$ 200 $ 600 1
Others Gemcitabine Gemcitabine vial (200 mg, 1 g, 2 g) - For cancer treatment. SDL $ 200 $ 600 1
Leukaemia Gemtuzumab ozogamicin Gemtuzumab ozogamicin powder for concentrate for solution for infusion vial (5 mg) Mylotarg In combination with daunorubicin and cytarabine for patients with previously untreated de novo CD33-positive acute myeloid leukaemia (AML), if they:
• do not have acute promyelocytic leukaemia,
• only start induction therapy while waiting for cytogenetic test results or after confirming favourable, intermediate or unknown (due to inconclusive test results) cytogenetic risk, and
• start consolidation therapy after confirming favourable, intermediate, or unknown cytogenetic risk.
MAF $ 3,200 $ 600 16
Leukaemia Gilteritinib Gilteritinib fumarate tablet (40 mg) Xospata Treatment of FLT-3 mutation positive relapsed / refractory acute myeloid leukaemia (AML).
Gilteritinib is not recommended as maintenance therapy for patients after HSCT.
MAF $ 9,200 $ 1,200 46
Breast cancer Goserelin acetate Goserelin acetate depot injection (3.6 mg, 10.8 mg) Zoladex Treatment of breast cancer in pre- and perimenopausal women in whom hormone therapy is specified. MAF $ 200 $ 600 1
Prostate cancer Goserelin acetate Goserelin acetate depot injection (3.6 mg, 10.8 mg) Zoladex 1) As primary therapy for men with locally advanced or metastatic prostate cancer
2) As neoadjuvant therapy, for 3 months to 2 years, in men receiving radical radiotherapy
3) For men with prostate cancer who have a biochemical relapse.
LHRH agonist is not recommended as monotherapy in patients with low risk prostate cancer
MAF $ 200 $ 600 1
Others Hydroxyurea Hydroxyurea capsule (500 mg) - For cancer treatment. SDL $ 200 $ 600 1
Leukaemia Ibrutinib Ibrutinib capsule (140 mg), and tablet (140 mg, 280 mg, 420 mg tablet) Imbruvica Ibrutinib in combination with rituximab or obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). No subsidy $ 2,000 $ 600 10
Leukaemia Ibrutinib Ibrutinib capsule (140 mg), and tablet (140 mg, 280 mg, 420 mg tablet) Imbruvica Monotherapy for patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least one prior therapy. No subsidy $ 2,000 $ 600 10
Leukaemia Ibrutinib Ibrutinib capsule (140 mg), and tablet (140 mg, 280 mg, 420 mg tablet) Imbruvica Monotherapy for patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are unsuitable for fludarabine-based therapy. No subsidy $ 2,000 $ 600 10
Lymphoma Ibrutinib Ibrutinib capsule (140 mg), and tablet (140 mg, 280 mg, 420 mg tablet) Imbruvica Ibrutinib as a single agent, or in combination with rituximab, for the treatment of Waldenstrom’s Macroglobulinaemia. No subsidy $ 2,000 $ 600 10
Lymphoma Ibrutinib Ibrutinib capsule (140 mg), and tablet (140 mg, 280 mg, 560 mg) Imbruvica Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. No subsidy $ 2,000 $ 600 10
Leukaemia Idarubicin Idarubicin solution for injection (5 mg/5 mL, 10 mg/10 mL) Zavedos CS Treatment of acute myeloid leukaemia (AML) in patients for remission induction. No subsidy $ 400 $ 600 2
Lymphoma Idelalisib Idelalisib tablet (150 mg) Zydelig Treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies. No subsidy $ 1,800 $ 600 9
Others Ifosfamide Ifosfamide infusion (1 g) Holoxan For cancer treatment. SDL $ 2,400 $ 600 12
Others Imatinib Imatinib tablet and capsule (100 mg, 400 mg) - For cancer treatment. SDL
(Veenat, Imatinib-AFT)
$ 200 $ 600 1
Skin cancer Imiquimod Imiquimod cream (5%) Aldara Treatment of actinic keratosis or superficial basal cell carcinoma. No subsidy $ 200 $ 600 1
Leukaemia Inotuzumab ozogamicin Inotuzumab ozogamicin powder for concentrate for solution for infusion (1 mg per vial) Besponsa Treatment of patients with relapsed or refractory CD22 positive B-precursor acute lymphoblastic leukemia (ALL) for:
- up to a maximum of three cycles for induction in a lifetime, and
- up to three additional cycles for consolidation in a lifetime in patients who achieve a complete response after induction
Patients with Philadelphia chromosome positive disease must have previously received a tyrosine kinase inhibitor before receiving inotuzumab.

Complete response is defined as a patient who:
a) has 5% or less bone marrow blasts; and
b) has no evidence of disease; and
c) has platelet count of more than 50,000 per microlitre; and
d) has absolute neutrophil count of more than 500 per microlitre.
MAF $ 9,600 $ 1,200 48
Others Interferon alfa 2a Interferon alfa 2a injection (3 million iu/ 0.5 mL) - For cancer treatment. SDL $ 400 $ 600 2
Others Irinotecan hydrochloride Irinotecan hydrochloride trihydrate vial (100 mg/5 mL) - For cancer treatment. SDL $ 200 $ 600 1
Multiple myeloma Ixazomib Ixazomib capsule (3 mg, 4 mg) Ninlaro Ixazomib in combination with lenalidomide and dexamethasone for patients with multiple myeloma who have received at least one prior therapy. MAF $ 2,000 $ 600 10
Neuroendocrine Lanreotide Lanreotide prolonged release (PR) injection (60 mg, 90 mg, 120 mg) Somatuline Autogel For the reduction of symptoms associated with carcinoid syndrome. No subsidy $ 600 $ 600 3
Neuroendocrine Lanreotide Lanreotide prolonged release (PR) injection (60 mg, 90 mg, 120 mg) Somatuline Autogel Treatment of neuroendocrine tumours of gastrointestinal or pancreatic origin. No subsidy $ 600 $ 600 3
Breast cancer Lapatinib Lapatinib tablet (250 mg) Tykerb Lapatinib in combination with an aromatase inhibitor for postmenopausal women with HR positive, HER2 positive metastatic breast cancer. MAF $ 600 $ 600 3
Breast cancer Lapatinib Lapatinib tablet (250 mg) Tykerb Lapatinib in combination with capecitabine for HER2 positive, advanced or metastatic breast cancer in patients whose disease has progressed after treatment with an anthracycline and, a taxane, and on prior trastuzumab therapy in the metastatic setting. MAF $ 600 $ 600 3
Tumour agnostic Larotrectinib Larotrectinib capsule (25 mg, 100 mg) and oral solution (2 g/100mL) Vitrakvi Treatment of patients with solid tumours that:
- have a NTRK gene fusion without a known acquired resistance mutation,
- are metastatic or where surgical resection is likely to result in severe morbidity, and
- have no satisfactory alternative treatments or that have progressed following treatment.
No subsidy $ 3,000 $ 600 15
Others L-asparaginase L-asparaginase injection (10,000 IU) Leunase For cancer treatment. SDL $ 1,000 $ 600 5
Others Lenalidomide Lenalidomide capsule (5 mg, 10 mg, 15 mg, 25 mg) - For cancer treatment. SDL
(Lenli)
$ 1,400 $ 600 7
Liver cancer Lenvatinib Lenvatinib capsule (4 mg, 10 mg) Lenvima Treatment of advanced unresectable hepatocellular carcinoma in patients with adequate liver function as assessed by the Child-Pugh scoring system, when used according to HSA-recommended dosing regimens. MAF $ 1,200 $ 600 6
Thyroid cancer Lenvatinib Lenvatinib capsule (4 mg, 10 mg) Lenvima Treatment of locally advanced or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. MAF $ 1,200 $ 600 6
Renal cancer Lenvatinib Lenvatinib capsule (4 mg, 10 mg) Lenvima Lenvatinib in combination with everolimus for previously treated advanced renal cell carcinoma. No subsidy $ 1,200 $ 600 6
Others Letrozole Letrozole tablet (2.5 mg) - For cancer treatment. SDL $ 200 $ 600 1
Breast cancer Leuprorelin acetate Leuprorelin acetate injection (3.75 mg, 11.25 mg) Lucrin Treatment of breast cancer in pre- and perimenopausal women in whom hormone therapy is specified. MAF $ 200 $ 600 1
Prostate cancer Leuprorelin acetate Leuprorelin acetate injection (3.75 mg, 5 mg/mL, 7.5 mg, 11.25 mg, 22.5 mg, 30 mg, 45 mg) Lucrin

Eligard
1) As primary therapy for men with locally advanced or metastatic prostate cancer
2) As neoadjuvant therapy, for 3 months to 2 years, in men receiving radical radiotherapy
3) For men with prostate cancer who have a biochemical relapse.
LHRH agonist is not recommended as monotherapy in patients with low risk prostate cancer
MAF $ 200 $ 600 1
Others Liposomal doxorubicin Doxorubicin hydrochloride (pegylated liposome) concentrate for infusion (20 mg/10 mL) - For cancer treatment. SDL
(Chemodox)
$ 1,400 $ 600 7
Pancreatic cancer Liposomal irinotecan Pegylated liposomal irinotecan concentrate for dispersion for infusion (43 mg/10 mL) Onivyde Liposomal irinotecan in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. No subsidy $ 1,000 $ 600 5
Others Lomustine Lomustine capsule (10 mg, 40 mg) - For cancer treatment. SDL $ 200 $ 600 1
Lung cancer Lorlatinib Lorlatinib tablet (25 mg, 100 mg) Lorviqua Treatment of locally advanced or metastatic ALK mutation-positive non-small-cell lung cancer. MAF $ 2,000 $ 600 10
Prostate cancer Lutetium PSMA Lutetium PSMA - Treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel-containing regimen. No subsidy $ 1,400 $ 600 7
Neuroendocrine Lutetium-177 peptide Lutetium-177 (177-Lu) peptide - Treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor-positive gastro-entero-pancreatic neuroendocrine tumours (NETs), including foregut, midgut, and hindgut NETs. No subsidy $ 1,200 $ 600 6
Others Megestrol Megestrol tablet (40 mg, 160 mg) - For cancer treatment. SDL $ 200 $ 600 1
Others Melphalan Melphalan injection (50 mg) Alkeran For cancer treatment. SDL $ 400 $ 600 2
Others Melphalan Melphalan tablet (2 mg) Alkeran For cancer treatment. SDL $ 200 $ 600 1
Others Mercaptopurine Mercaptopurine tablet (50 mg) - For cancer treatment. SDL $ 200 $ 600 1
Others Mercaptopurine Mercaptopurine oral suspension (2000 mg/100 mL) - For cancer treatment. No subsidy $ 1,000 $ 600 5
Thyroid cancer Meta-iodobenzylguanidine Meta-iodobenzylguanidine [I-131] injection for therapeutic use (185 to 740 MBq/mL) - Radiation therapy of tumours arising from cells originating embryologically from the neural crest, pheochromocytomas, neuroblastomas, carcinoids and medullary carcinomas of the thyroid gland. No subsidy $ 3,000 $ 600 15
Others Methotrexate Methotrexate tablet (2.5 mg) - For cancer treatment. SDL $ 200 $ 600 1
Others Methotrexate Methotrexate injection (50 mg/2 mL, 1g/10 mL) - For cancer treatment. SDL $ 400 $ 600 2
Others Methylprednisolone Methylprednisolone injection (500 mg, 1 g) - For cancer treatment. SDL $ 200 $ 600 1
Leukaemia Midostaurin Midostaurin capsule (25 mg) Rydapt Treatment of FLT-3-mutation positive acute myeloid leukaemia (AML) in combination with standard intensive induction and consolidation chemotherapy. Standard induction chemotherapy must include cytarabine and an anthracycline.
Midostaurin is not recommended for maintenance therapy.
MAF $ 2,400 $ 600 12
Leukaemia Midostaurin Midostaurin capsule (25 mg) Rydapt Treatment of aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM-AHN) or mast cell leukaemia (MCL). No subsidy $ 2,400 $ 600 12
Others Mitomycin Mitomycin injection (2 mg, 10 mg) - For cancer treatment. SDL $ 200 $ 600 1
Neuroendocrine Mitotane Mitotane tablet (500 mg) - For symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma. No subsidy $ 3,000 $ 600 15
Others Mitoxantrone Mitoxantrone vial (20 mg/10 mL) - For cancer treatment. SDL $ 1,000 $ 600 5
Breast cancer Nab-paclitaxel Paclitaxel - albumin bound nanoparticles injectable suspension (100 mg) Abraxane Monotherapy for metastatic breast cancer in patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated. MAF $ 1,000 $ 600 5
Lung cancer Nab-paclitaxel Paclitaxel - albumin bound nanoparticles injectable suspension (100 mg) Abraxane Nab-paclitaxel in combination with carboplatin, for previously untreated locally advanced or metastatic non-small cell lung cancer in patients who are not candidates for curative surgery or radiation therapy. MAF $ 1,000 $ 600 5
Pancreatic cancer Nab-paclitaxel Paclitaxel - albumin bound nanoparticles injectable suspension (100 mg) Abraxane Nab-paclitaxel in combination with gemcitabine, for previously untreated metastatic adenocarcinoma of the pancreas. MAF $ 1,000 $ 600 5
Others Nab-paclitaxel Paclitaxel - albumin bound nanoparticles injectable suspension (100 mg) Abraxane For cancer treatment in patients who are intolerant to paclitaxel. MAF $ 1,000 $ 600 5
Leukaemia Nelarabine Nelarabine injection (250 mg/50 mL) - Treatment of T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma that has not responded to or has relapsed following treatment with at least 2 chemotherapy regimens. No subsidy $ 1,000 $ 600 5
Leukaemia Nilotinib Nilotinib capsule (50 mg, 150 mg, 200 mg) Tasigna Treatment of adults with treatment-resistant or treatment-intolerant chronic myeloid leukaemia (CML) in chronic phase or accelerated phase; or children with treatment-resistant or treatment-intolerant CML in chronic phase. MAF $ 1,200 $ 600 6
Leukaemia Nilotinib Nilotinib capsule (50 mg, 150 mg, 200 mg) Tasigna Treatment of newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase. MAF $ 1,200 $ 600 6
Ovarian cancer Niraparib Niraparib tablet (100 mg) Zejula Maintenance monotherapy for patients with advanced epithelial high-grade ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
Treatment should be continued until disease progression or unacceptable toxicity or a maximum of 36 months.
No subsidy $ 1,600 $ 600 8
Ovarian cancer Niraparib Niraparib tablet (100 mg) Zejula Maintenance monotherapy for patients with platinum-sensitive relapsed BRCA-mutated high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
Patients must not have received prior treatment with a PARP inhibitor for ovarian cancer. Treatment should be continued until disease progression or unacceptable toxicity.
No subsidy $ 1,600 $ 600 8
Head and neck cancer Nivolumab Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) Opdivo For patients with recurrent or metastatic squamous cell cancer of the head and neck whose disease progressed within six months of starting platinum-based chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for this condition in the recurrent or metastatic setting. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. MAF $ 1,800 $ 600 9
Lung cancer Nivolumab Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) Opdivo Treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. MAF $ 1,800 $ 600 9
Lymphoma Nivolumab Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) Opdivo Treatment of patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after an autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for this condition in the relapsed or refractory setting. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if the person has an allogeneic stem cell transplant or the disease progresses. MAF $ 1,800 $ 600 9
Renal cancer Nivolumab Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) Opdivo For previously treated advanced renal cell carcinoma (RCC). Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for advanced RCC. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. MAF $ 1,800 $ 600 9
Renal cancer Nivolumab Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) Opdivo For untreated intermediate- or poor-risk advanced renal cell carcinoma, following induction treatment with nivolumab in combination with ipilimumab. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. MAF $ 1,800 $ 600 9
Skin cancer Nivolumab Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) Opdivo Adjuvant treatment of completely resected malignant melanoma in patients with lymph node involvement. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Maximum duration of treatment: 12 months. MAF $ 1,800 $ 600 9
Skin cancer Nivolumab Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) Opdivo Monotherapy for advanced unresectable or metastaticmalignant melanoma. Patients must not have received prior treatment with a PD-1 inhibitor or ipilimumab for advanced unresectable or metastatic malignant melanoma. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. MAF $ 1,800 $ 600 9
Skin cancer Nivolumab Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL, 240 mg/24 mL) Opdivo Treatment of advanced unresectable or metastatic malignant melanoma, following induction treatment with nivolumab in combination with ipilimumab. The dose of nivolumab should not exceed 3 mg/kg every 2 weeks. MAF $ 1,800 $ 600 9
Upper gastrointestinal cancer Nivolumab Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) Opdivo Treatment of patients with unresectable locally advanced or recurrent gastric or gastroesophageal junction (GEJ) adenocarcinoma after 2 or more prior systemic therapies. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for unresectable locally advanced or recurrent gastric or GEJ cancer. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. MAF $ 1,800 $ 600 9
Upper gastrointestinal cancer Nivolumab Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL, 240 mg/24 mL) Opdivo Adjuvant treatment of completely resected oesophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy. Maximum treatment duration: 12 months. MAF $ 1,800 $ 600 9
Upper gastrointestinal cancer Nivolumab Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL, 240 mg/24 mL) Opdivo Nivolumab in combination with fluoropyrimidine and platinum-based chemotherapy for untreated, unresectable advanced or metastatic HER2 negative gastric cancer, gastroesophageal junction cancer or oesophageal adenocarcinoma. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. MAF $ 1,800 $ 600 9
Upper gastrointestinal cancer Nivolumab Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL, 240 mg/24 mL) Opdivo Treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for this condition in the unresectable advanced, recurrent or metastatic setting. MAF $ 1,800 $ 600 9
Bladder cancer Nivolumab Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) Opdivo Treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) after receiving platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for locally advanced or metastatic UC. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. No subsidy $ 1,800 $ 600 9
Colorectal cancer Nivolumab Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) Opdivo Treatment of unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for unresectable or metastatic MSI-H or dMMR CRC. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. No subsidy $ 1,800 $ 600 9
Liver cancer Nivolumab Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) Opdivo Treatment of advanced unresectable hepatocellular carcinoma (HCC) in patients with disease progression after 1 or more prior lines of systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for advanced unresectable HCC. The dose of nivolumab should not exceed 3mg/kg every 2 weeks. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. No subsidy $ 1,800 $ 600 9
Renal cancer Nivolumab Nivolumab concentrate for solution for infusion (40 mg/4mL, 100 mg/10mL) Opdivo Nivolumab in combination with cabozantinib for untreated advanced renal cell carcinoma. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. No subsidy $ 1,800 $ 600 9
Colorectal cancer Nivolumab Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) Opdivo Nivolumab in combination with ipilimumab for treatment of unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for unresectable or metastatic MSI-H or dMMR CRC. The doses of nivolumab and ipilimumab should not exceed: 3mg/kg nivolumab and 1mg/kg ipilimumab every 3 weeks for 4 doses, followed by nivolumab 240mg every 2 weeks or 480mg every 4 weeks as a single agent. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. Re-induction with ipilimumab is not allowed. No subsidy $ 1,800 $ 600 9
Liver cancer Nivolumab Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) Opdivo Nivolumab in combination with ipilimumab for treatment of advanced unresectable hepatocellular carcinoma (HCC) in patients with disease progression after 1 or more prior lines of systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for advanced unresectable HCC. The doses of nivolumab and ipilimumab should not exceed: 1mg/kg nivolumab and 3mg/kg ipilimumab every 3 weeks for 4 doses, followed by nivolumab 240mg every 2 weeks or 480mg every 4 weeks as a single agent. Treatment with nivolumab should be stopped at 2 years, or earlier if disease progresses. Re-induction with ipilimumab is not allowed. No subsidy $ 1,800 $ 600 9
Lung cancer Nivolumab Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL) Opdivo Nivolumab in combination with ipilimumab and 2 cycles of platinum-based chemotherapy, for untreated metastatic or recurrent non-small cell lung cancer (NSCLC) in patients with no EGFR or ALK genomic tumour mutations. Treatment with nivolumab and ipilimumab should be stopped at 2 years, or earlier if disease progresses. No subsidy $ 1,800 $ 600 9
Renal cancer Nivolumab plus ipilimumab Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL)

Ipilimumab injection concentrate (50 mg/10 mL)
Opdivo


Yervoy
Nivolumab in combination with ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma. The doses of nivolumab and ipilimumab should not exceed: 3mg/kg nivolumab and 1mg/kg ipilimumab every 3 weeks for 4 doses. Re-induction with ipilimumab is not allowed. MAF $ 5,200 $ 600 26
Skin cancer Nivolumab plus ipilimumab Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL, 240 mg/24 mL)

Ipilimumab injection concentrate (50 mg/10 mL)
Opdivo


Yervoy
Nivolumab in combination with ipilimumab for the treatment of advanced unresectable or metastatic malignant melanoma. The doses of nivolumab and ipilimumab should not exceed: 1mg/kg nivolumab and 3mg/kg ipilimumab every 3 weeks for 4 doses. MAF $ 5,200 $ 600 26
Lymphoma Obinutuzumab Obinutuzumab concentrate for solution for infusion (1000 mg/40 mL) Gazyva Obinutuzumab in combination with bendamustine, for the treatment of follicular lymphoma that has not responded to or progressed within 6 months after treatment with rituximab or a rituximab-containing regimen. Patients must not have received obinutuzumab for follicular lymphoma. Maintenance treatment with obinutuzumab should be stopped at 2 years, or earlier if disease progresses. MAF $ 1,800 $ 600 9
Lymphoma Obinutuzumab Obinutuzumab concentrate for solution for infusion (1000 mg/40 mL) Gazyva Obinutuzumab in combination with chemotherapy, for previously untreated stage II bulky, III or IV follicular lymphoma. Patients achieving at least a partial remission may continue to receive maintenance treatment with obinutuzumab monotherapy. Maintenance treatment with obinutuzumab should be stopped after 2 years, or earlier if disease progresses. No subsidy $ 1,800 $ 600 9
Others Octreotide Octreotide long-acting depot injection (20 mg, 30 mg) Sandostatin LAR For cancer treatment. SDL $ 600 $ 600 3
Breast cancer Olaparib Olaparib tablet (100 mg, 150 mg) Lynparza Treatment of germline BRCA-mutated, HER2 negative, locally advanced or metastatic breast cancer in patients previously treated with chemotherapy. MAF $ 1,600 $ 600 8
Ovarian cancer Olaparib Olaparib tablet (100 mg, 150 mg) Lynparza Maintenance monotherapy for patients with advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
Treatment should be continued until disease progression or unacceptable toxicity or a maximum of 24 months.
MAF $ 1,600 $ 600 8
Ovarian cancer Olaparib Olaparib tablet (100 mg, 150 mg) Lynparza Maintenance monotherapy for patients with platinum-sensitive relapsed BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
Patients must not have received prior treatment with a PARP inhibitor for ovarian cancer. Treatment should be continued until disease progression or unacceptable toxicity.
MAF $ 1,600 $ 600 8
Ovarian cancer Olaparib Olaparib tablet (100 mg, 150 mg) Lynparza Olaparib in combination with bevacizumab biosimilar (subsidised brand) as maintenance treatment of patients with advanced homologous recombination deficiency (HRD) positive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy in combination with bevacizumab biosimilar.
Treatment with olaparib should be continued until disease progression or unacceptable toxicity or for a maximum of 24 months.
MAF $ 1,600 $ 600 8
Pancreatic cancer Olaparib Olaparib tablet (100 mg, 150 mg) Lynparza Maintenance treatment of patients with deleterious or suspected deleterious germline BRCA mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. MAF $ 1,600 $ 600 8
Prostate cancer Olaparib Olaparib tablet (100 mg, 150 mg) Lynparza Treatment of patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene BRCA1/2 and/or ATM-mutations (germline and/or somatic) whose disease has progressed following prior treatment with abiraterone or a second-generation anti-androgen. MAF $ 1,600 $ 600 8
Ovarian cancer Olaparib Olaparib tablet (100 mg, 150 mg) Lynparza Olaparib in combination with bevacizumab (non-subsidised brand) as maintenance treatment of patients with advanced homologous recombination deficiency (HRD) positive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy in combination with bevacizumab.
Treatment with olaparib should be continued until disease progression or unacceptable toxicity or for a maximum of 24 months.
No subsidy $ 1,600 $ 600 8
Lung cancer Osimertinib Osimertinib tablet (40 mg, 80 mg) Tagrisso Treatment of patients with locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer whose disease has progressed on or after EGFR TKI therapy. MAF $ 2,400 $ 600 12
Lung cancer Osimertinib Osimertinib tablet (40 mg, 80 mg) Tagrisso Adjuvant treatment after tumour resection in patients with stage IB to IIIA non-small-cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. Treatment should be continued until disease recurrence or unacceptable toxicity or for a maximum of 3 years. No subsidy $ 2,400 $ 600 12
Lung cancer Osimertinib Osimertinib tablet (40 mg, 80 mg) Tagrisso For previously untreated locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer. No subsidy $ 2,400 $ 600 12
Others Oxaliplatin Oxaliplatin injection (50 mg, 100 mg, 200 mg) - For cancer treatment. SDL $ 200 $ 600 1
Others Paclitaxel Paclitaxel vial (150 mg/25 mL, 300 mg/50 mL) - For cancer treatment. SDL $ 200 $ 600 1
Breast cancer Palbociclib Palbociclib capsule (75 mg, 100 mg, 125 mg) and tablet (75 mg, 100 mg, 125 mg) Ibrance Palbociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for HR positive, HER2 negative, advanced or metastatic breast cancer. MAF $ 800 $ 600 4
Breast cancer Palbociclib Palbociclib capsule (75 mg, 100 mg, 125 mg) and tablet (75 mg, 100 mg, 125 mg) Ibrance Palbociclib in combination with fulvestrant for treating HR positive, HER2 negative, advanced or metastatic breast cancer in patients who have received prior endocrine therapy. MAF $ 800 $ 600 4
Others Panitumumab Panitumumab concentrate for solution for infusion (100 mg/5 mL) Vectibix For cancer treatment. SDL $ 1,000 $ 600 5
Others Pazopanib Pazopanib tablet (200 mg, 400 mg) Votrient For cancer treatment. SDL $ 1,600 $ 600 8
Bladder cancer Pembrolizumab Pembrolizumab solution for infusion (100 mg/4 mL) Keytruda Treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) after receiving platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for locally advanced or metastatic UC. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. MAF $ 1,800 $ 600 9
Breast cancer Pembrolizumab Pembrolizumab solution for infusion (100 mg/4 mL) Keytruda Pembrolizumab in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple negative breast cancer whose tumours express PD-L1 (CPS ≥10) and who have not received prior chemotherapy for metastatic disease. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. MAF $ 1,800 $ 600 9
Colorectal cancer Pembrolizumab Pembrolizumab solution for infusion (100 mg/4 mL) Keytruda For untreated metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. MAF $ 1,800 $ 600 9
Head and neck cancer Pembrolizumab Pembrolizumab solution for infusion (100 mg/4 mL) Keytruda Monotherapy for untreated unresectable, recurrent or metastatic squamous cell cancer of the head and neck (RMSCCHN) with PD-L1 CPS≥1. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. MAF $ 1,800 $ 600 9
Head and neck cancer Pembrolizumab Pembrolizumab solution for infusion (100 mg/4 mL) Keytruda Pembrolizumab in combination with platinum-based chemotherapy, for untreated unresectable, recurrent or metastatic squamous cell cancer of the head and neck (RMSCCHN) with PD-L1 CPS≥1. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. MAF $ 1,800 $ 600 9
Lung cancer Pembrolizumab Pembrolizumab solution for infusion (100 mg/4 mL) Keytruda For untreated metastatic non-small cell lung cancer (NSCLC) in patients whose tumours express PD-L1 with a tumour proportion score ≥50%, with no EGFR or ALK genomic tumour aberrations. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. MAF $ 1,800 $ 600 9
Lung cancer Pembrolizumab Pembrolizumab solution for infusion (100 mg/4 mL) Keytruda Pembrolizumab in combination with carboplatin and paclitaxel for untreated metastatic squamous non-small cell lung cancer (NSCLC). Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. MAF $ 1,800 $ 600 9
Lung cancer Pembrolizumab Pembrolizumab solution for infusion (100 mg/4 mL) Keytruda Pembrolizumab in combination with pemetrexed and platinum chemotherapy, for untreated metastatic non-squamous non-small cell lung cancer (NSCLC) in patients with no EGFR or ALK genomic tumour aberrations. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. MAF $ 1,800 $ 600 9
Lung cancer Pembrolizumab Pembrolizumab solution for infusion (100 mg/4 mL) Keytruda Treatment of patients with metastatic non-small cell lung cancer (NSCLC), whose tumours express PD-L1 with a tumour proportion score ≥1% and had disease progression during or following platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. MAF $ 1,800 $ 600 9
Lymphoma Pembrolizumab Pembrolizumab solution for infusion (100 mg/4 mL) Keytruda Treatment of patients with relapsed or refractory classical Hodgkin lymphoma (cHL), who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for this condition in the relapsed or refractory setting. Treatment with pembrolizumab should be stopped at 2 years, or earlier if the person has a stem cell transplant or the disease progresses. MAF $ 1,800 $ 600 9
Skin cancer Pembrolizumab Pembrolizumab solution for infusion (100 mg/4 mL) Keytruda Adjuvant treatment of completely resected malignant melanoma in patients with lymph node involvement. Maximum duration of treatment: 12 months. MAF $ 1,800 $ 600 9
Skin cancer Pembrolizumab Pembrolizumab solution for infusion (100 mg/4 mL) Keytruda Treatment of advanced unresectable or metastatic malignant melanoma. Patients must not have received a PD-1 inhibitor or ipilimumab for advanced unresectable or metastatic malignant melanoma. MAF $ 1,800 $ 600 9
Upper gastrointestinal cancer Pembrolizumab Pembrolizumab solution for infusion (100 mg/4 mL) Keytruda Pembrolizumab in combination with fluoropyrimidine and platinum-based chemotherapy for untreated, locally advanced unresectable or metastatic carcinoma of the oesophagus or HER2 negative gastroesophageal junction (GEJ) adenocarcinoma (tumours with epicenter 1 to 5 cm above the GEJ) that is not amenable to surgical resection or definitive chemoradiation. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. MAF $ 1,800 $ 600 9
Bladder cancer Pembrolizumab Pembrolizumab solution for infusion (100 mg/4 mL) Keytruda Treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. No subsidy $ 1,800 $ 600 9
Bladder cancer Pembrolizumab Pembrolizumab solution for infusion (100 mg/4 mL) Keytruda Treatment of patients with locally advanced or metastatic urothelial carcinoma whose tumours express PD-L1 with a combined positive score (CPS) ≥10, and who are not eligible for cisplatin-containing chemotherapy. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. No subsidy $ 1,800 $ 600 9
Liver cancer Pembrolizumab Pembrolizumab solution for infusion (100 mg/4 mL) Keytruda Treatment of advanced unresectable hepatocellular carcinoma (HCC) in patients with disease progression after 1 or more prior lines of systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for advanced unresectable HCC. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. No subsidy $ 1,800 $ 600 9
Lung cancer Pembrolizumab Pembrolizumab solution for infusion (100 mg/4 mL) Keytruda Pembrolizumab in combination with carboplatin and nab- paclitaxel for untreated metastatic squamous non-small cell lung cancer (NSCLC). Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. No subsidy $ 1,800 $ 600 9
Lymphoma Pembrolizumab Pembrolizumab solution for infusion (100 mg/4 mL) Keytruda Treatment of patients with refractory primary mediastinal B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for PMBCL. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses No subsidy $ 1,800 $ 600 9
Merkel cell cancer Pembrolizumab Pembrolizumab solution for infusion (100 mg/4 mL) Keytruda Treatment of metastatic Merkel cell carcinoma. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. No subsidy $ 1,800 $ 600 9
Tumour agnostic Pembrolizumab Pembrolizumab solution for infusion (100 mg/4 mL) Keytruda Treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours that have progressed following prior treatment and who have no satisfactory alternative treatment options. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for the same MSI-H or dMMR solid tumour in the unresectable or metastatic setting. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. No subsidy $ 1,800 $ 600 9
Renal cancer Pembrolizumab plus axitinib Pembrolizumab solution for infusion (100 mg/4 mL)

Axitinib tablet (1 mg, 5 mg)
Keytruda


Inlyta
Pembrolizumab in combination with axitinib for untreated advanced renal cell carcinoma. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. No subsidy $ 3,000 $ 600 15
Endometrial cancer Pembrolizumab plus lenvatinib Pembrolizumab solution for infusion (100 mg/4 mL)

Lenvatinib capsule (4 mg, 10 mg)
Keytruda

Lenvima
Pembrolizumab in combination with lenvatinib for the treatment of patients with advanced endometrial carcinoma (EC) that is not microsatellite instability-high (non-MSI-H) or mismatch repair deficient (non-dMMR), who have disease progression following prior platinum chemotherapy and are not candidates for curative surgery or radiation. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for advanced EC. Treatment with pembrolizumab should be stopped at 2 years, or earlier if disease progresses. No subsidy $ 3,000 $ 600 15
Others Pemetrexed Pemetrexed injection (100 mg, 500 mg) - For cancer treatment. SDL $ 200 $ 600 1
Breast cancer Pertuzumab Pertuzumab concentrate for solution for infusion (420 mg/14 mL) Perjeta Pertuzumab in combination with trastuzumab and a taxane for HER2 positive metastatic or locally recurrent breast cancer, in patients without prior treatment for metastatic disease. Treatment with pertuzumab should be stopped if disease progresses. No subsidy $ 2,400 $ 600 12
Breast cancer Pertuzumab Pertuzumab concentrate for solution for infusion (420 mg/14 mL) Perjeta Pertuzumab in combination with trastuzumab and chemotherapy for adjuvant treatment of high-risk (with positive nodes) HER2 positive early breast cancer for a maximum duration of 1 year. No subsidy $ 2,400 $ 600 12
Breast cancer Pertuzumab Pertuzumab concentrate for solution for infusion (420 mg/14 mL) Perjeta Pertuzumab in combination with trastuzumab and chemotherapy for neoadjuvant treatment of HER2 positive locally advanced, inflammatory or early stage (tumour >2 cm in diameter or node positive) breast cancer for 4 to 6 cycles. Following surgery, patients may continue with trastuzumab with or without pertuzumab for a total of 1 year of anti-HER2 treatment. No subsidy $ 2,400 $ 600 12
Breast cancer Pertuzumab + Trastuzumab Pertuzumab + trastuzumab fixed dose combination injection (1200 mg/600 mg and 600 mg/600 mg) Phesgo Fixed-dose pertuzumab and trastuzumab subcutaneous injection in combination with a taxane for treating HER2-positive metastatic or locally recurrent breast cancer, in patients without prior treatment for metastatic disease. Treatment with pertuzumab should be stopped if disease progresses. No subsidy $ 2,400 $ 600 12
Breast cancer Pertuzumab + Trastuzumab Pertuzumab + trastuzumab fixed dose combination injection (1200 mg/600 mg and 600 mg/600 mg) Phesgo Fixed-dose pertuzumab and trastuzumab subcutaneous injection in combination with chemotherapy for adjuvant treatment of high-risk (with positive nodes) HER2-positive early breast cancer for a maximum duration of 1 year. No subsidy $ 2,400 $ 600 12
Breast cancer Pertuzumab + Trastuzumab Pertuzumab + trastuzumab fixed dose combination injection (1200 mg/600 mg and 600 mg/600 mg) Phesgo Fixed-dose pertuzumab and trastuzumab subcutaneous injection in combination with chemotherapy for neoadjuvant treatment of HER2-positive locally advanced, inflammatory or early stage (tumour >2 cm in diameter or node positive) breast cancer for 4 to 6 cycles. Following surgery, patients may continue with trastuzumab with or without pertuzumab for a total of 1 year of anti-HER2 treatment. No subsidy $ 2,400 $ 600 12
Multiple myeloma Pomalidomide Pomalidomide capsule (1 mg, 2 mg, 3 mg, 4 mg) Pomalyst Pomalidomide in combination with bortezomib or cyclophosphamide, plus dexamethasone, for patients with multiple myeloma who have received at least one prior therapy. MAF $ 2,000 $ 600 10
Multiple myeloma Pomalidomide Pomalidomide capsule (1 mg, 2 mg, 3 mg, 4 mg) Pomalyst Pomalidomide in combination with dexamethasone for patients with multiple myeloma who have received at least two prior therapies, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy. MAF $ 2,000 $ 600 10
Leukaemia Ponatinib Ponatinib tablet (15 mg) Iclusig Treatment of chronic, accelerated, or blast phase chronic myeloid leukaemia (CML) in patients:
• whose disease is resistant to imatinib or dasatinib or nilotinib, and who have the T315I mutation OR
• whose disease is resistant to both nilotinib and dasatinib OR
• whose disease is resistant to nilotinib or dasatinib and who are intolerant of/contraindicated to the other drug.
MAF $ 1,200 $ 600 6
Leukaemia Ponatinib Ponatinib tablet (15 mg) Iclusig Treatment of patients with Philadelphia chromosome positive acute lymphoblastic leukaemia who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation. MAF $ 1,200 $ 600 6
Others Prednisolone Prednisolone tablet (1 mg, 5 mg, 20 mg) and syrup (10 mg/5 mL) - For cancer treatment. SDL $ 200 $ 600 1
Others Procarbazine Procarbazine capsule (50 mg) - For cancer treatment. SDL $ 800 $ 600 4
Prostate cancer Radium-223 Radium-223 solution for injection (1100 kBq/mL) Xofigo Treatment of patients with castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastatic disease. No subsidy $ 1,400 $ 600 7
Colorectal cancer Ramucirumab Ramucirumab concentrate for solution for infusion (100 mg/10 mL, 500 mg/50 mL) Cyramza Ramucirumab in combination with FOLFIRI for treating metastatic colorectal cancer that has progressed on first-line systemic therapy. No subsidy $ 1,800 $ 600 9
Liver cancer Ramucirumab Ramucirumab concentrate for solution for infusion (100 mg/10 mL, 500 mg/50 mL) Cyramza Treatment of advanced unresectable hepatocellular carcinoma in patients with disease progression after 1 or more prior lines of systemic therapy, and who have serum alpha-fetoprotein (AFP) of ≥400 ng/ml, and have adequate liver function as assessed by the Child-Pugh scoring system. No subsidy $ 1,800 $ 600 9
Upper gastrointestinal cancer Ramucirumab Ramucirumab concentrate for solution for infusion (100 mg/10 mL, 500 mg/50 mL) Cyramza Ramucirumab as monotherapy for patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. No subsidy $ 1,800 $ 600 9
Upper gastrointestinal cancer Ramucirumab Ramucirumab concentrate for solution for infusion (100 mg/10 mL, 500 mg/50 mL) Cyramza Ramucirumab in combination with paclitaxel for patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. No subsidy $ 1,800 $ 600 9
Colorectal cancer Regorafenib Regorafenib tablet (40 mg) Stivarga Treatment of metastatic colorectal cancer that has been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and if RAS wild-type, an anti-EGFR therapy. MAF $ 1,800 $ 600 9
Liver cancer Regorafenib Regorafenib tablet (40 mg) Stivarga Treatment of advanced unresectable hepatocellular carcinoma in patients with disease progression after 1 or more prior lines of systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system. MAF $ 1,800 $ 600 9
Sarcoma Regorafenib Regorafenib tablet (40 mg) Stivarga Treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumours (GISTs) who have been previously treated with imatinib mesylate. MAF $ 1,800 $ 600 9
Breast cancer Ribociclib Ribociclib tablet (200 mg) Kisqali Ribociclib in combination with an aromatase inhibitor as initial endocrine-based therapy for HR positive, HER2 negative, advanced or metastatic breast cancer. MAF $ 800 $ 600 4
Breast cancer Ribociclib Ribociclib tablet (200 mg) Kisqali Ribociclib in combination with fulvestrant for HR positive, HER2 negative, advanced or metastatic breast cancer in patients who have received prior endocrine therapy. MAF $ 800 $ 600 4
Lymphoma Rituximab Rituximab solution for subcutaneous injection (1400 mg/11.7 mL) Mabthera Rituximab (subcutaneous) for maintenance treatment of patients with follicular lymphoma who have responded to induction therapy. No subsidy $ 1,000 $ 600 5
Lymphoma Rituximab Rituximab solution for subcutaneous injection (1400 mg/11.7 mL) Mabthera Rituximab (subcutaneous) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), for the treatment of CD20+ diffuse large B-cell non-Hodgkin lymphoma. No subsidy $ 1,000 $ 600 5
Lymphoma Rituximab Rituximab solution for subcutaneous injection (1400 mg/11.7 mL) Mabthera Rituximab (subcutaneous) in combination with cyclophosphamide, vincristine, prednisone (CVP), for the treatment of previously untreated patients with stage III-IV follicular lymphoma. No subsidy $ 1,000 $ 600 5
Others Rituximab Rituximab concentrate for infusion (100 mg/10 mL, 500 mg/50 mL) Mabthera
Rixathon
For cancer treatment. No subsidy $ 1,000 $ 600 5
Others Rituximab Rituximab biosimilar concentrate for infusion (100 mg/10 mL, 500 mg/50 mL) Truxima For cancer treatment. SDL (Truxima) $ 1,000 $ 600 5
Lymphoma Romidepsin Romidepsin powder for solution for infusion (10 mg) - Treatment of cutaneous T-cell lymphoma in patients who have received at least one prior systemic therapy. No subsidy $ 1,800 $ 600 9
Lymphoma Romidepsin Romidepsin powder for solution for infusion (10 mg) - Treatment of peripheral T-cell lymphoma in patients who have received at least one prior therapy. No subsidy $ 1,800 $ 600 9
Myeloproliferative neoplasms Ruxolitinib Ruxolitinib tablet (5 mg, 15 mg, 20 mg) Jakavi Treatment of patients with:
1) intermediate-1 risk myelofibrosis with severe disease-related symptoms or splenomegaly that are resistant, refractory or intolerant to available therapy; or
2) intermediate-2 or high-risk myelofibrosis with disease-related splenomegaly or symptoms.
MAF $ 2,000 $ 600 10
Breast cancer Sacituzumab govitecan Sacituzumab govitecan powder for solution for infusion (180 mg) Trodelvy Treatment of unresectable locally advanced or metastatic triple negative breast cancer in patients who have received two or more prior systemic therapies, at least one of them for metastatic disease. No subsidy $ 1,800 $ 600 9
Multicentric Castleman's disease Siltuximab Siltuximab powder for infusion (100 mg) Sylvant Treatment of patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. No subsidy $ 3,000 $ 600 15
Thyroid cancer Sodium iodide Sodium iodide [I-131] capsule (37 to 6000 MBq) - For thyroid residue ablation after surgery of differentiated thyroid cancer, and treatment of iodine-accumulating metastases. No subsidy $ 1,600 $ 600 8
Neuroendocrine Somatropin Somatropin prefilled pen (5 mg/1.5 mL, 10 mg/1.5 mL)
Somatropin powder and solvent for solution for injection (4 mg, 5.3 mg/mL)
Somatropin solution for injection (5.83 mg/mL, 8 mg/mL)
- Replacement therapy in adults with growth hormone deficiency associated with benign or malignant hypothalamic or pituitary neoplasms. MAF $ 600 $ 600 3
Others Sorafenib Sorafenib tablet (200 mg) Nexavar For cancer treatment. SDL $ 1,200 $ 600 6
Neuroendocrine Streptozocin Streptozocin injection (1 g) Zanosar Streptozocin in combination with 5-fluorouracil for inoperable, advanced or metastatic, progressive and/or symptomatic, well-differentiated, G1 or G2 neuroendocrine tumours of pancreatic origin. No subsidy $ 800 $ 600 4
Neuroendocrine Sunitinib Sunitinib capsule (12.5 mg, 25 mg, 37.5 mg, 50 mg) - Treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors with disease progression. No subsidy $ 1,600 $ 600 8
Renal cancer Sunitinib Sunitinib capsule (12.5 mg, 25 mg, 37.5 mg, 50 mg) - Treatment of advanced renal cell carcinoma. No subsidy $ 1,600 $ 600 8
Sarcoma Sunitinib Sunitinib capsule (12.5 mg, 25 mg, 37.5 mg, 50 mg) - Treatment of patients with unresectable and/or metastatic malignant gastrointestinal stromal tumours (GISTs) who have had an inadequate response to imatinib mesylate treatment due to resistance or intolerance. No subsidy $ 1,600 $ 600 8
Breast cancer Talazoparib Talazoparib capsule (0.25 mg, 1 mg) Talzenna Treatment of germline BRCA-mutated, HER2 negative, locally advanced or metastatic breast cancer in patients previously treated with chemotherapy. No subsidy $ 1,600 $ 600 8
Others Tamoxifen Tamoxifen tablet (20 mg) - For cancer treatment. SDL $ 200 $ 600 1
Others Tegafur + gimeracil + oteracil Tegafur + gimeracil + oteracil potassium capsule (20 mg/5.8 mg/19.6 mg, 25 mg/7.25 mg/24.5 mg) TS-ONE For cancer treatment. No subsidy $ 200 $ 600 1
Others Temozolomide Temozolomide capsule (20 mg, 100 mg) - For cancer treatment. SDL $ 1,800 $ 600 9
Lung cancer Tepotinib Tepotinib tablet (225 mg) Tepmetko Treatment of metastatic non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition factor gene exon 14 skipping (METex14sk) alterations. MAF $ 1,600 $ 600 8
Others Thalidomide Thalidomide capsule (50 mg) - For cancer treatment. SDL $ 400 $ 600 2
Others Tioguanine Tioguanine tablet (40 mg) - For cancer treatment. SDL $ 1,600 $ 600 8
Others Topotecan Topotecan injection (4 mg) - For cancer treatment. No subsidy $ 200 $ 600 1
Sarcoma Trabectedin Trabectedin powder for injection (1 mg) Yondelis Treatment of patients with advanced or metastatic soft tissue sarcoma, after failure of anthracyclines and ifosfamide (unless unsuitable). No subsidy $ 1,200 $ 600 6
Others Trastuzumab Trastuzumab powder for IV infusion (440 mg) Herceptin
Kanjinti
Trazimera
For cancer treatment. No subsidy $ 600 $ 600 3
Others Trastuzumab Trastuzumab solution for SC injection (600 mg/5 mL) Herceptin For cancer treatment. No subsidy $ 600 $ 600 3
Others Trastuzumab Trastuzumab biosimilar powder for IV infusion (440 mg) Ogivri
Herzuma
For cancer treatment. SDL (Ogivri, Herzuma) $ 600 $ 600 3
Breast cancer Trastuzumab emtansine Trastuzumab emtansine powder for concentrate for infusion solution (100 mg, 160 mg) Kadcyla Adjuvant treatment of HER2 positive early breast cancer in patients with residual invasive disease, after neoadjuvant treatment with trastuzumab and a taxane. Maximum 14 cycles. No subsidy $ 2,400 $ 600 12
Breast cancer Trastuzumab emtansine Trastuzumab emtansine powder for concentrate for infusion solution (100 mg, 160 mg) Kadcyla Treatment of HER2 positive, locally advanced, unresectable, or metastatic breast cancer in patients who have received prior treatment with trastuzumab and a taxane. No subsidy $ 2,400 $ 600 12
Others Tretinoin Tretinoin capsule (10 mg) Vesanoid For cancer treatment. SDL $ 800 $ 600 4
Colorectal cancer Trifluridine + tipiracil Trifluridine + tipiracil tablet (15 mg/6.14 mg, 20 mg/8.19 mg) Lonsurf Treatment of metastatic colorectal cancer that has been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and if RAS wild-type, an anti-EGFR therapy. No subsidy $ 1,800 $ 600 9
Upper gastrointestinal cancer Trifluridine + tipiracil Trifluridine + tipiracil tablet (15 mg/6.14 mg, 20 mg/8.19 mg) Lonsurf Treatment of patients with unresectable locally advanced or recurrent gastric or gastroesophageal junction adenocarcinoma after 2 or more prior systemic therapies. No subsidy $ 1,800 $ 600 9
Prostate cancer Triptorelin Triptorelin injection (3.75 mg, 11.25 mg, 22.5 mg) - Treatment of locally advanced or metastatic, hormone-dependent prostate cancer. No subsidy $ 200 $ 600 1
Breast cancer Tucatinib Tucatinib tablet (50 mg, 150 mg) Tukysa For the treatment of locally advanced unresectable or metastatic HER2-positive breast cancer in combination with trastuzumab and capecitabine in patients who have received one or more prior anti-HER2-based regimens in the metastatic setting. No subsidy $ 2,400 $ 600 12
Leukaemia Venetoclax Venetoclax tablet (10 mg, 50 mg, 100 mg) Venclexta Monotherapy for patients with chronic lymphocytic leukaemia (CLL) who are unsuitable for fludarabine-based therapy, following combination treatment with obinutuzumab. (Maximum treatment duration of obinutuzumab is 6 cycles and venetoclax is 12 months) MAF $ 3,000 $ 600 15
Leukaemia Venetoclax Venetoclax tablet (10 mg, 50 mg, 100 mg) Venclexta Venetoclax in combination with rituximab biosimilar (subsidised brand) for patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. Maximum treatment duration of rituximab is 6 cycles and venetoclax is 24 months. MAF $ 3,000 $ 600 15
Leukaemia Venetoclax Venetoclax tablet (10 mg, 50 mg, 100 mg) Venclexta Treatment of newly diagnosed acute myeloid leukaemia (AML) in combination with a hypomethylating agent or low-dose cytarabine in patients who are ineligible for intensive chemotherapy. No subsidy $ 3,000 $ 600 15
Leukaemia Venetoclax Venetoclax tablet (10 mg, 50 mg, 100 mg) Venclexta Venetoclax in combination with rituximab (non-subsidised brand) for patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. Maximum treatment duration of rituximab is 6 cycles and venetoclax is 24 months. No subsidy $ 3,000 $ 600 15
Leukaemia Venetoclax plus obinutuzumab Venetoclax tablet (10 mg, 50 mg, 100 mg)

Obinutuzumab concentrate for solution for infusion (1000 mg/40 mL)
Venetoclax

Gazyva
Venetoclax in combination with obinutuzumab for patients with previously untreated chronic lymphocytic leukaemia (CLL) who are unsuitable for fludarabine-based therapy. Maximum treatment duration of obinutuzumab is 6 cycles and venetoclax is 12 months. MAF $ 5,400 $ 600 27
Others Vinblastine sulfate Vinblastine sulfate vial (10 mg) - For cancer treatment. SDL $ 200 $ 600 1
Others Vincristine sulfate Vincristine sulfate vial (1 mg) - For cancer treatment. SDL $ 200 $ 600 1
Bladder cancer Vinflunine Vinflunine concentrate for solution for infusion (50 mg/2 mL, 100 mg/4 mL, 250 mg/10 mL) Javlor Treatment of patients with locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy. No subsidy $ 1,800 $ 600 9
Others Vinorelbine Vinorelbine injection (50 mg/5 mL) - For cancer treatment. SDL $ 400 $ 600 2
Breast cancer Vinorelbine Vinorelbine capsule (20 mg, 30 mg) - Treatment of advanced breast cancer. No subsidy $ 400 $ 600 2
Lung cancer Vinorelbine Vinorelbine capsule (20 mg, 30 mg) - Treatment of non-small cell lung cancer. No subsidy $ 400 $ 600 2
Skin cancer Vismodegib Vismodegib capsule (150 mg) Erivedge Treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation. No subsidy $ 3,000 $ 600 15